DOCSLIB.ORG

Astrazeneca Clinical Programmes Summary

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

AstraZeneca Clinical Programmes Summary 2Q 2014 Results Update The following information about ongoing AstraZeneca clinical studies in Phases I-IV has been created with selected information from clinicaltrials.gov to facilitate understanding of key aspects of our clinical programmes and is correct to the best of our knowledge as at 30 June 2014. It includes estimated timelines with regards to study completion and first external presentations of primary data. These estimates are subject to change as programmes recruit faster or slower than anticipated. Project postings on clinicaltrials.gov are updated on a continuous basis as projects progress. For the most up to date information on our clinical programmes please visit clinicaltrials.gov. 2Q 2014: 4 new NME pivotal study starts contributing to growing late stage pipeline Pivotal study starts in 2Q 2014 Number of NMEs in pivotal studies 14 roxadustat (HIF) CKD & ESRD tremelimumab (CTLA-4) mesothelioma 11 NMEs AZD9291 (EGFR) 2L NSCLC 9-10 PD-L1 (MEDI4736) 8 NSCLC 8 6 benralizumab (IL-5R) COPD LEs olaparib (PARP) adjuvant BRCAm BC HY 2013 FY 2013 HY 2014 Oncology RIA CVMD 2 2 2014: Continued strong momentum in late stage pipeline BACE (AZD3293) Alzheimer’s disease tenapanor (NHE3) ESRD anifrolumab (IFN-αR) SLE roxadustat (HIF) sifalimumab (IFN-α) CKD & ESRD SLE NMEs tremelimumab (CTLA-4) mavrilimumab (GM-CSF) mesothelioma RA AZD9291 (EGFR) cediranib (VEGF) 2L NSCLC ovarian PD-L1 (MEDI4736) tralokinumab (IL-13) CD19 (MEDI-551) NSCLC severe asthma CLL benralizumab (IL-5R) Forxiga (SGLT-2) PD-L1 (MEDI4736) COPD Type 1 diabetes additional tumours brodalumab (IL-17R) Symbicort (ICS/LABA) PD-L1 combinations psoriatic arthritis mild asthma additional tumours olaparib (PARP) AZD9291 (EGFR) AZD9291 combinations adjuvant BRCAm BC 1L NSCLC EGFRM+ NSCLC LEs olaparib (PARP) PD-L1 +/- tremelimumab metastatic BRCAm BC SCCHN selumetinib (MEK) PD-L1 + tremelimumab metastatic uveal melanoma NSCLC Pivotal study starts Pivotal study decision Pivotal study decision 1H 2014 made 1H 2014 pending 2H 2014 3 Oncology RIA CVMD Neuroscience 3 Movements since Q1 2014 update New to Phase I New to Phase II New to Pivotal Study New to Registration NMEs NMEs NMEs MCH (AZD1979) IFNβ (AZD9412) (SNG001)¥ AZD9291 obesity asthma, COPD EGFR T790M+ NSCLC Androgen (AZD5312) TSLP (MEDI9929) PD-L1 (MEDI4736) prostate cancer asthma Stage III NSCLC CD19 (MEDI-551) + rituximab LABA/LAMA/ICS (PT010) Roxadustat (HIF) haems COPD anaemia in CKD/ESRD Amyloidβ (MEDI1814) Volitinib (MET) Tremelimumab (CTLA-4) Alzheimer’s solid tumours mesothelioma PD-L1 (MEDI4736) + Iressa EGFR M+ NSCLC Additional indications PD-L1 (MEDI4736) + PD-1 Benralizumab (IL-5R) (MEDI0680) solid tumours COPD CD40L (MEDI4920) PD-L1 (MEDI4736) Primary Sjögren’s syndrome 3L NSCLC RSV sF+GLA –SE (MEDI7510) olaparib RSV prophylaxis PARP adjuvant breast cancer RSV Mab YTE (MEDI8897) RSV prophylaxis Tremelimumab (CTLA-4) + Iressa EGFR M+ NSCLC Added back to pipeline SGRM (AZD7594) asthma, COPD Removed from Phase I Removed from Phase II Removed from Phase III Removed from Registration NMEs NMEs Epanova (US)* CXCR2 (AZD4721) CXCR2 (AZD5069) hypertriglyceridaemia COPD asthma HtN9 vaccine (MEDI9287) IL-1R (MEDI8968) avian flu COPD, HS Additional indications Tenapanor (NHE3) fluid retention ¥ New business development; *Approved Q2 2014 4 A growing and accelerating late stage pipeline Phase 1 Phase 2 Phase 3 / Registration 35 New Molecular Entities 24 New Molecular Entities 14 New Molecular Entities Small molecule Large molecule Small molecule Large molecule Small molecule Large molecule PIM (AZD1208) DLL-4 (MEDI0639) WEE-1 (AZD1775) CD19 (MEDI-551) AZD9291 (EGFRm+ t790m+) PD-L1 (MEDI4736) haems solid tumours ovarian, 1L NSCLC CLL, DLBCL NSCLC NSCLC Androgen (AZD5312) PD-1 (MEDI0680) TORC ½ (AZD2014) IGF (MEDI-573) olaparib (PARP) Moxetumomab (CD22) prostate solid tumours solid tumours metastatic breast cancer BRCA ovarian, gastric, breast HCL ATR (AZD6738) CEA BiTE (MEDI-565) FGFR (AZD4547) anifrolumab selumetinib (MEK) tremelimumab (CTLA-4) CLL, H&N GI tumours solid tumours IFNaR SLE 2L KRAS+ve NSCLC, uveal melanoma, DTC mesothelioma PI3Kβδ (AZD8186) ANG-2 (MEDI3617) AKT (AZD5363) AZD9412 (Inhaled βIFN) lesinurad (URAT1) brodalumab (IL-17R) solid tumours solid tumours breast cancer asthma, COPD gout psoriasis, psoriatic arthritis STAT3 (AZD9150) mOX40 (MEDI6469) volitinib (MET) mavrilimumab (GM-CSFR) LABA/LAMA (PT003) benralizumab (IL-5R) haems + solids solid tumours solid tumours rheumatoid arthritis COPD severe asthma, COPD TLR9 (AZD1419) CD40L (MEDI4920) MABA (AZD2115) IL-23 (MEDI2070) LAMA (PT001) asthma Primary Sjögren’s Syndrome COPD Crohn’s COPD SGRM (AZD7594) B7RP1 (MEDI5872) LABA/LAMA/ICS (PT010) α4β7 (MEDI7183) roxadustat (HIF) asthma, COPD SLE COPD Crohn’s, ulcerative colitis anaemia CKD/ESRD p38 inhibitor (AZD7624) LCAT (MEDI6012) URAT1 (RDEA3170) TSLP (MEDI9929) Movantik (PAMORA) COPD ACS gout asthma opioid induced constipation TLR7 agonist (AZD8848) Rh-Factor II (MEDI8111) Hormone mod. (AZD4901) sifalimumab (IFNa) CAZ AVI (BLI/cephalosporin) asthma rauma/bleeding PCOS SLE SBI MCH (AZD1979) Amyloidβ (MEDI1814) tenapanor (AZD1722) IL-13 (tralokinumab) obesity Alzheimer’s NHE3 inhibitor ESRD-Pi/CKD asthma, IPF BACE (AZD3293) MEDI-550 MPO (AZD3241) Alzheimer's pandemic influenza virus vaccine Multiple System Atrophy New approvals 1 New Molecular Entity NMDA (AZD6423) staph alpha tox. (MEDI4893) H3R (AZD5213) suicidal ideation SSI Tourette’s, neuropathic pain Small molecule Large molecule ATM AVI MEDI7510 Oxazolidinone (AZD5847) Epanova BL/BLI SBI RSV sF+GLA-SE RSV prevention TB hypertriglyceridaemia GyrAr (AZD0914) MEDI8897 BLI/cephalosporin (CXL) serious infection RSV Mab YTE passive RSV prophylaxis MRSA PRVV (MEDI-559) Paediatric RSV vaccine Oncology combinations PD-L1 + dabrafenib + trametinib PD-L1 + PD-1 melanoma solid tumours Oncology RIA CVMD Neuroscience Infection PD-L1 + Iressa CD-19 + rituximab Terminations in Q2 2014 EGFR M+ NSCLC haems AZD5069 (asthma) in Phase 2, MEDI8968 (COPD, HS) in Phase 2, AZD4721 (COPD) in Phase 1, MEDI9287 (avian flu) in Phase 1 (AZD5069 and AZD4721 termination decisions made in July 2014) PD-L1 + tremelimumab tremelimumab + Iressa solid5 tumours| NSCLC Pipeline table as of 30th June 2014 5 2H 2014: Key data readouts Compound Indication Milestone lesinurad gout Ph III topline results CAZ AVI cIAI Ph III topline results brodalumab psoriasis Ph III topline results sifalimumab SLE Ph IIb (ACR) mavrilimumab RA Ph IIb (ACR) MEDI4736 solid tumours Ph I (ESMO) MEDI4736 + tremelimumab NSCLC Ph I (ESMO) AZD9291 NSCLC Ph I (ESMO) AZD3293 Alzheimer’s disease Ph I (CTAD) 6 6 2H 2014: Key regulatory milestones Compound Indication Potential milestones Iressa EGFRm NSCLC US filing Movantik OIC US approval (PDUFA 16 Sep 2014) Movantik OIC EU approval Brilinta ACS JP approval olaparib PSR BRCAm ovarian cancer US approval (PDUFA 3 Jan 2015) Xigduo XR type 2 diabetes US approval (PDUFA 29 Oct 2014) saxagliptin/dapagliflozin FDC type 2 diabetes US filing lesinurad gout EU, US filing CAZ AVI cIAI EU filing 7 7 Potential NME & LE submissions 2014-16 Myalept EU lipodystrophy PT003 LABA/LAMA COPD PT001 LAMA COPD CAZ AVI EU brodalumab* PD-L1 (MEDI4736) cephalosporin/BLI SBI IL-17R psoriasis NSCLC lesinurad AZD9291 US/EU/JP benralizumab NMEs URAT1 gout EGFR T790M NSCLC IL-5R asthma olaparib US selumetinib roxadustat (FG-4592) CH PARP PSR BRCAm ovarian MEK uveal melanoma HIF anaemia CKD/ESRD 2014 2015 2016 Bydureon Dual Chamber Pen JP Brilinta PEGASUS US/EU/JP Brilinta EUCLID US/EU GLP-1 T2D ADP receptor antagonist ADP receptor antagonist Onglyza SAVOR US/EU Bydureon Autoinjector US/EU Brilinta SOCRATES US/EU/JP DPP-4 T2D GLP-1 T2D ADP receptor antagonist saxa-dapa FDC US/EU Iressa IMPRESS EU/JP/CH Caprelsa US/EU/JP DPP-4/SGLT-2 T2D EGFRm+ NSCLC differentiated thyroid cancer Iressa US Faslodex US/EU/JP/CH EGFRm+ NSCLC ER antagonist olaparib SOLO-2 US/EU/JP/CH LEs PSR BRCAm ovarian cancer olaparib OlympiAD US/EU/JP New since 1Q 14 results update PARP metastatic breast cancer lesinurad FDC US/EU SURI/XOI gout 8 * Filing is the responsibility of partner Oncology RIA CVMD Neuroscience Infection 8 AstraZeneca LE development programmes 2Q 2014 Results Update Brilinta/Brilique (ADP receptor antagonist) PARTHENON development programme Patient Phase # of Design Endpoint(s) Status Population Study patients Patients with Phase III N = 21000 • ARM 1: Ticagrelor 90 mg BiD • Composite of CV death, • FSI Q4 10 prior MI PEGASUS • ARM 2: Ticagrelor 60 mg BiD non-fatal MI and non-fatal • LSI Q2 13 • ARM 3: Placebo BiD stroke • Est. completion date Q1 15 NCT01225562 on a background of ASA • Est. external presentation Q3 15 (ESC) Global study – 31 countries Patients with Phase III N = 13500 • ARM 1: Ticagrelor 90 mg BiD • Composite of CV death, • FSI Q3 12 PAD EUCLID • ARM 2: Clopidogrel 75 mg QD non-fatal MI and ischemic • LSI Q1 14 monotherapy trial stroke • Est. completion date Q1 16 NCT01732822 • Est. external presentation 2016 Global study – 28 countries Patients with Phase III N = 9600 • ARM 1: Ticagrelor 90 mg BiD • Composite of non-fatal • FSI Q1 14 Stroke or TIA SOCRATES • ARM 2: ASA 100mg/day stroke, non-fatal MI and all • Est. completion date Q4 15 monotherapy trial cause death • Est. external presentation 2016 NCT01994720 Global study – approx. 32 countries Patients with Phase III N = 17000 • ARM 1: Ticagrelor 90 mg BiD • Composite of CV death, • FSI Q1 14 Type 2 Diabetes THEMIS • ARM 2: Placebo BiD non-fatal MI and non-fatal • Est. completion date Q1 17 and Coronary on a background of ASA if not contra stroke • Est. external presentation beyond Artery Disease NCT01991795 indicated or not tolerated planning horizon without a previous history Global study – approx. 40 countries of MI or Stroke 10 Forxiga/Farxiga (SGLT-2 inhibitor) Type 2 Diabetes development programme Patient Phase # of Design Endpoint(s) Status Population Study patients Typ 2 diabetes Phase III/IV N = 17150 • ARM 1: Dapagliflozin 10 mg QD + standard • Time to first • FSI Q2 13 mellitus with DECLARE of care therapy QD event included in • LSI Q2 16 high risk for CV • ARM 2: Placebo + standard of care therapy the composite • Est.
Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES

    Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
  • University of Iowa Instruments in Space

    University of Iowa Instruments in Space

    University of Iowa Instruments in Space A-D13-089-5 Wind Van Allen Probes Cluster Mercury Earth Venus Mars Express HaloSat MMS Geotail Mars Voyager 2 Neptune Uranus Juno Pluto Jupiter Saturn Voyager 1 Spaceflight instruments designed and built at the University of Iowa in the Department of Physics & Astronomy (1958-2019) Explorer 1 1958 Feb. 1 OGO 4 1967 July 28 Juno * 2011 Aug. 5 Launch Date Launch Date Launch Date Spacecraft Spacecraft Spacecraft Explorer 3 (U1T9)58 Mar. 26 Injun 5 1(U9T68) Aug. 8 (UT) ExpEloxrpelro r1e r 4 1915985 8F eJbu.l y1 26 OEGxOpl o4rer 41 (IMP-5) 19697 Juunlye 2 281 Juno * 2011 Aug. 5 Explorer 2 (launch failure) 1958 Mar. 5 OGO 5 1968 Mar. 4 Van Allen Probe A * 2012 Aug. 30 ExpPloiorenre 3er 1 1915985 8M Oarc. t2. 611 InEjuxnp lo5rer 45 (SSS) 197618 NAouvg.. 186 Van Allen Probe B * 2012 Aug. 30 ExpPloiorenre 4er 2 1915985 8Ju Nlyo 2v.6 8 EUxpKlo 4r e(rA 4ri1el -(4IM) P-5) 197619 DJuenc.e 1 211 Magnetospheric Multiscale Mission / 1 * 2015 Mar. 12 ExpPloiorenre 5e r 3 (launch failure) 1915985 8A uDge.c 2. 46 EPxpiolonreeerr 4130 (IMP- 6) 19721 Maarr.. 313 HMEaRgCnIe CtousbpeShaetr i(cF oMxu-1ltDis scaatelell itMe)i ssion / 2 * 2021081 J5a nM. a1r2. 12 PionPeioenr e1er 4 1915985 9O cMt.a 1r.1 3 EExpxlpolorerer r4 457 ( S(IMSSP)-7) 19721 SNeopvt.. 1263 HMaalogSnaett oCsupbhee Sriact eMlluitlet i*scale Mission / 3 * 2021081 M5a My a2r1. 12 Pioneer 2 1958 Nov. 8 UK 4 (Ariel-4) 1971 Dec. 11 Magnetospheric Multiscale Mission / 4 * 2015 Mar.
  • Remarkably Similar CTLA-4 Binding Properties of Therapeutic Ipilimumab and Tremelimumab Antibodies

    Remarkably Similar CTLA-4 Binding Properties of Therapeutic Ipilimumab and Tremelimumab Antibodies

    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 40), pp: 67129-67139 Research Paper Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies Mengnan He1,2,*, Yan Chai1,*, Jianxun Qi1, Catherine W.H. Zhang3, Zhou Tong4, Yi Shi1, Jinghua Yan4, Shuguang Tan1 and George F. Gao1,2 1CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China 2University of Chinese Academy of Sciences, Beijing 100049, China 3ImmuFuCell Biotechnology Co., Ltd., Beijing 100102, China 4CAS Key Laboratory of Microbial Physiological and Metabolic Engineering, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China *These authors have contributed equally to this work Correspondence to: George F. Gao, email: [email protected] Shuguang Tan, email: [email protected] Keywords: ipilimumab, CTLA-4, complex structure, tremelimumab Received: April 04, 2017 Accepted: April 21, 2017 Published: May 19, 2017 Copyright: He et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Monoclonal antibody based immune checkpoint blockade therapies have achieved clinical successes in management of malignant tumors. As the first monoclonal antibody targeting immune checkpoint molecules entered into clinics, the molecular basis of ipilimumab-based anti-CTLA-4 blockade has not yet been fully understood. In the present study, we report the complex structure of ipilimumab and CTLA-4. The complex structure showed similar contributions from VH and VL of ipilimumab in binding to CTLA-4 front β-sheet strands.
  • New Biological Therapies: Introduction to the Basis of the Risk of Infection

    New Biological Therapies: Introduction to the Basis of the Risk of Infection

    New biological therapies: introduction to the basis of the risk of infection Mario FERNÁNDEZ RUIZ, MD, PhD Unit of Infectious Diseases Hospital Universitario “12 de Octubre”, Madrid ESCMIDInstituto de Investigación eLibraryHospital “12 de Octubre” (i+12) © by author Transparency Declaration Over the last 24 months I have received honoraria for talks on behalf of • Astellas Pharma • Gillead Sciences • Roche • Sanofi • Qiagen Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Paul Ehrlich (1854-1915) • “side-chain” theory (1897) • receptor-ligand concept (1900) • “magic bullet” theory • foundation for specific chemotherapy (1906) • Nobel Prize in Physiology and Medicine (1908) (together with Metchnikoff) Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author 1981: B-1 antibody (tositumomab) anti-CD20 monoclonal antibody 1997: FDA approval of rituximab for the treatment of relapsed or refractory CD20-positive NHL 2001: FDA approval of imatinib for the treatment of chronic myelogenous leukemia Infections and biologicals: a real concern? (two-hour symposium): New biological therapies: introduction to the ESCMIDbasis of the risk of infection eLibrary © by author Functional classification of targeted (biological) agents • Agents targeting soluble immune effector molecules • Agents targeting cell surface receptors
  • ESCMID Online Lecture Library @ by Author

    ESCMID Online Lecture Library @ by Author

    The diverse monoclonal antibodies in immunology and medical oncology: relevance for infectious diseases Dra. Isabel Ruiz Camps ESCMIDHospital Online Universitari Lecture Vall d’Hebron Library @ by authorBarcelona Disclosure • Astellas • Gilead Sciences • MSD • Novartis • Pfizer ESCMID Online Lecture Library @ by author A huge topic for such a ESCMIDshort Online time Lecture Library @ by author natalizumab antiTNF antiCD20: rituximab, obinutuzumab, ofatumumab gemtuzumab (antiCD33) alemtuzumab (antiCD52) daratumumab (antiCD38) Inotuzumab (antiCD22) Brentuximab (CD30) Seculinumab (anti IL-17) Tocilizumab (antiIL6) PI3K inhibitors PARP inh: olaparib, Guselkumab (anti IL12/23) rucaparib (copanlisib, more ... Roxulitinib, tofacitinib (JAK inh) Urelumab (CD137 R) Immunotherapy: ipilimumab TK inhibitors : Imatinib, dasatinib, Belimumab (antiBAFF) (CTLA-4), tremelimumab (CTLA-4), masitinib, bosutinib, nilotinib, fostamatinib nivolimumab (PD1/PDL1), (spleen), ibrutinib (BTK), alisertib (ATK), Pembrolizumab (PD1), more...... afatinib Cabozantinib: MET, RET, VEGFR2 HER2/neu:ESCMID trastuzumab, lapatinib Online VEGFR: bevacizumabLecture, LibrarymTOR: temsirolimus sorafenib, sunitinib EGFR: cetuximab, panitumumab, MAPK inh: dabrafenib, vemurafenib erlotinib, gefitinib Selinexor (XPO1 antagonist) @ by author Trametinib (MEK inh) Index • Background • Biological therapies for immunological diseases and risk of infection • Biological therapies for cancer – Target pathways – Risk of infection • Prevention ESCMID Online Lecture Library @ by author What are
  • Chandra-Hetgs Characterization of an Outflowing Wind in the Accreting Millisecond Pulsar Igr J17591−2342

    Chandra-Hetgs Characterization of an Outflowing Wind in the Accreting Millisecond Pulsar Igr J17591−2342

    Draft version February 27, 2019 Typeset using LATEX twocolumn style in AASTeX61 CHANDRA-HETGS CHARACTERIZATION OF AN OUTFLOWING WIND IN THE ACCRETING MILLISECOND PULSAR IGR J17591−2342 Michael A. Nowak,1 Adamantia Paizis,2 Gaurava Kumar Jaisawal,3 Jer´ ome^ Chenevez,3 Sylvain Chaty,4 Francis Fortin,4 Jer´ ome^ Rodriguez,4 andJ orn¨ Wilms5 1Physics Dept., CB 1105, Washington University, One Brookings Drive, St. Louis, MO 63130-4899 2Istituto Nazionale di Astrofisica, INAF-IASF, Via Alfonso Corti 12, I-20133 Milano, Italy 3National Space Institute, Technical University of Denmark, Elektrovej 327-328, DK-2800 Lyngby, Denmark 4AIM, CEA, CNRS, Universit´eParis-Saclay, Universit´eParis-Diderot, Sorbonne Paris Cit´e,F-91191 Gif sur Yvette, France 5Dr. Karl Remeis-Observatory & ECAP, University of Erlangen-Nuremberg, Sternwartstr. 7, 96049 Bamberg, Germany (Received 2019 January; Accepted 2019 February) Submitted to ApJ ABSTRACT IGR J17591−2342 is an accreting millisecond X-ray pulsar discovered in 2018 August in scans of the Galactic bulge and center by the INTEGRAL X-ray and gamma-ray observatory. It exhibited an unusual outburst profile with multiple peaks in the X-ray, as observed by several X-ray satellites over three months. Here we present observations of this source performed in the X-ray/gamma-ray and near infrared domains, and focus on a simultaneous observation performed with the Chandra-High Energy Transmission Gratings Spectrometer (HETGS) and the Neutron Star Interior Composition Explorer (NICER). HETGS provides high resolution spectra of the Si-edge region, which yield clues as to the source's distance and reveal evidence (at 99.999% significance) of an outflow with a velocity of 2 800 km s−1.
  • Final Release from the Extended Baryon

    Final Release from the Extended Baryon

    Draft version August 19, 2019 Preprint typeset using LATEX style emulateapj v. 12/16/11 THE SIXTEENTH DATA RELEASE OF THE SLOAN DIGITAL SKY SURVEYS: FINAL RELEASE FROM THE EXTENDED BARYON OSCILLATION SPECTROSCOPIC SURVEY, AND FIRST RELEASE FROM APOGEE-2S V´ıctor Silva Aguirre1, Romina Ahumada2, Carlos Allende Prieto3,4, Andres´ Almeida5, Friedrich Anders6,7, Scott F. Anderson8, Brett H. Andrews9, Borja Anguiano10, Riccardo Arcodia11, Marie Aubert12, Santiago Avila13,14, Vladimir Avila-Reese15, Christophe Balland16, Kat Barger17, Sarbani Basu18, Julian Bautista19, Rachael L. Beaton20, Timothy C. Beers21, Chad F. Bender22, Mariangela Bernardi23, Matthew Bershady24,25, Florian Beutler19, Dmitry Bizyaev26, Michael R. Blanton27,Med´ eric´ Boquien28, Jura Borissova29,30, Jo Bovy31,32, W.N. Brandt33,34,35, Jonathan Brinkmann26, Joel R. Brownstein36, Kevin Bundy37, Martin Bureau38, Adam Burgasser39, Mariana Cano-D´ıaz15, Raffaella Capasso40,41,42, Ricardo Carrera43, Solene` Chabanier44, Brian Cherinka45, Cristina Chiappini6, Peter Doohyun Choi46, Haeun Chung47, Nicolas Clerc48, Damien Coffey11, Julia M. Comerford49, Johan Comparat11, Luiz da Costa50,51, Marie-Claude Cousinou12, Kevin Covey52, Jeffrey D. Crane20, Katia Cunha51,22, Gabriele da Silva Ilha53,50, Yu Sophia Dai54, Sanna B. Damsted55, Danny Horta Darrington56, James W. Davidson Jr.10, Kyle Dawson36, Nikhil De57,17, Axel de la Macorra58, Nathan De Lee59, Alice Deconto Machado53,50, Sylvain de la Torre60, Flavia Dell'Agli3,4, Helion´ du Mas des Bourboux36, Aleksandar M. Diamond-Stanic61, Sean Dillon62,63, John Donor17, Niv Drory64, Chris Duckworth65, Tom Dwelly11, Garrett Ebelke10, Arthur Davis Eigenbrot24, Yvonne P. Elsworth66, Mike Eracleous33,34, Ghazaleh Erfanianfar11, Stephanie Escoffier12, Xiaohui Fan22, Emily Farr8, Jose´ G. Fernandez-Trincado´ 67,68, Diane Feuillet69, Alexis Finoguenov55, Patricia Fofie62,70, Amelia Fraser-McKelvie71, Peter M.
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories

    Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories

    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
  • Tables-Of-Phase-3-Mabs.Pdf

    Tables-Of-Phase-3-Mabs.Pdf

    Table 3. Monoclonal antibodies in Phase 2/3 or 3 clinical studies for cancer indications Most advanced Primary sponsoring company INN or code name Molecular format Target(s) phase Phase 3 indications Therapeutic area Janssen Research & Development, LLC JNJ-56022473 Humanized mAb CD123 Phase 2/3 Acute myeloid leukemia Cancer Murine IgG1, Actinium Pharmaceuticals Iomab-B radiolabeled CD45 Phase 3 Acute myeloid leukemia Cancer Humanized IgG1, Seattle Genetics Vadastuximab talirine ADC CD33 Phase 3 Acute myeloid leukemia Cancer TG Therapeutics Ublituximab Chimeric IgG1 CD20 Phase 3 Chronic lymphocytic leukemia Cancer Xencor XMAB-5574, MOR208 Humanized IgG1 CD19 Phase 2/3 Diffuse large B-cell lymphoma Cancer Moxetumomab Murine IgG1 dsFv, AstraZeneca/MedImmune LLC pasudotox immunotoxin CD22 Phase 3 Hairy cell leukemia Cancer Humanized scFv, Viventia Bio Oportuzumab monatox immunotoxin EpCAM Phase 3 Bladder cancer Cancer scFv-targeted liposome containing Merrimack Pharmaceuticals MM-302 doxorubicin HER2 Phase 2/3 Breast cancer Cancer MacroGenics Margetuximab Chimeric IgG1 HER2 Phase 3 Breast cancer Cancer Gastric cancer or gastroesophageal junction Gilead Sciences GS-5745 Humanized IgG4 MMP9 Phase 3 adenocarcinoma; ulcerative colitis (Phase 2/3) Cancer; Immune-mediated disorders Depatuxizumab Humanized IgG1, AbbVie mafodotin ADC EGFR Phase 2/3 Glioblastoma Cancer AstraZeneca/MedImmune LLC Tremelimumab Human IgG2 CTLA4 Phase 3 NSCLC, head & neck cancer, bladder cancer Cancer NSCLC, head & neck cancer, bladder cancer, breast AstraZeneca/MedImmune
  • The Two Tontti Tudiul Lui Hi Ha Unit

    The Two Tontti Tudiul Lui Hi Ha Unit

    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M

    Antibodies to Watch in 2021 Hélène Kaplona and Janice M

    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
  • Structural Basis for Cancer Immunotherapy by the First-In-Class

    Structural Basis for Cancer Immunotherapy by the First-In-Class

    Structural basis for cancer immunotherapy by the PNAS PLUS first-in-class checkpoint inhibitor ipilimumab Udupi A. Ramagopala,1,2, Weifeng Liua,b,1, Sarah C. Garrett-Thomsona,1, Jeffrey B. Bonannoa, Qingrong Yanb,3, Mohan Srinivasanc, Susan C. Wongc, Alasdair Bellc,4, Shilpa Mankikarc, Vangipuram S. Ranganc, Shrikant Deshpandec, Alan J. Kormanc,5, and Steven C. Almoa,5 aDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY 10461; bDepartment of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY 10461; and cBiologics Discovery California, Bristol–Myers Squibb, Redwood City, CA 94063 Edited by James P. Allison, MD Anderson Cancer Center, University of Texas, Houston, TX, and approved April 6, 2017 (received for review November 1, 2016) Rational modulation of the immune response with biologics repre- expressed on activated T effector cells as a result of ligand binding. sents one of the most promising and active areas for the realization Extrinsic effects of CTLA-4 are the consequence of the ability of of new therapeutic strategies. In particular, the use of function CTLA-4 expressed on Tregs to remove B7 ligands from the surface blocking monoclonal antibodies targeting checkpoint inhibitors such of dendritic cells or antigen presenting cells, resulting in significantly as CTLA-4 and PD-1 have proven to be highly effective for the reduced suppression (16). This regulatory mechanism of trans- systemic activation of the human immune system to treat a wide endocytosis may also be operative in activated T effector cells (17, range of cancers. Ipilimumab is a fully human antibody targeting 18). CTLA-4–B7 interactions also have intrinsic effects on Treg, CTLA-4 that received FDA approval for the treatment of metastatic dampening their proliferation or activation (19).